Promis Neurosciences Inc (PMN)

$9.24 +0.25 (2.78%)
Market Cap 19.35M
Revenue (ttm) 0.00
Net Income (ttm) 2.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,023
Avg Vol 32,886
Day's Range N/A - N/A
Shares Out 2.15M
Stochastic %K 88%
Beta -0.05
Analysts Strong Sell
Price Target $46.50

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Fax: 416 847 6899
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
7DAYSDIMENSIONS
7DAYSDIMENSIONS Dec. 15 at 5:08 PM
$PMN who has the feeling that this dog will jump up in the sky before Xmas? Gut feeling anyone?
1 · Reply
tommy_john
tommy_john Dec. 11 at 12:33 AM
$PMN more upside
0 · Reply
Misterx69
Misterx69 Dec. 10 at 9:04 PM
$PMN
0 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS Dec. 10 at 8:15 PM
$PMN I don't recall seeing a stock going up after a reverse split. Here is one... My first shares were bought at 312.50$... it's a total disaster.
2 · Reply
DaBullRunner
DaBullRunner Dec. 8 at 11:38 PM
$PMN watching closely …. 🚨KITT🚨smart money adding here as this is heavily lagging behind its peers RR and SERV…. Sooner or later this will pay me HUGE I’m even willing to put some of my COIN TSLA profits into KITT👇💰💰💰
0 · Reply
TheUnmaker
TheUnmaker Dec. 8 at 2:52 AM
$TNXP and $PMN my top biotechnology stocks for this week. Huge potential!
1 · Reply
TheUnmaker
TheUnmaker Dec. 6 at 5:28 PM
$TNXP added to my position yesterday after seeing the support at $19.50. This company has always had huge potential. I'm also watch $PMN after the recent split. Low floater 2.15M shares with an end of day pop.
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 3:59 PM
HC Wainwright & Co. has updated their rating for ProMIS Neurosciences ( $PMN ) to Buy with a price target of 18.
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 1 at 2:58 PM
$PMN has popped 8% higher to 7% (~30Kv) moments ago, follow for more volatility.
0 · Reply
TwongStocks
TwongStocks Nov. 28 at 6:57 PM
Today's reverse split results. $IVF 1 for 8 Previous close $0.2529, $2.0232 split-adjusted Intraday high $2.25 Today's close $2.2450 🟢Up 10.96% $PLRZ 1 for 6 Previous close $0.522, $3.132 split-adjusted Intraday high $3.64 Today's close $3.21 🟢Up 2.49% $PMN 1 for 25 Previous close $0.2895, $7.2375 split-adjusted Intraday high $7.92 Today's close $6.76 🔴Down 6.60%
0 · Reply
Latest News on PMN
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 10, 2025, 7:30 AM EST - 5 days ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:30 AM EST - 14 days ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 14 days ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

ProMIS Neurosciences Announces Reverse Stock Split

Nov 24, 2025, 8:00 AM EST - 21 days ago

ProMIS Neurosciences Announces Reverse Stock Split

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 12, 2025, 7:00 AM EST - 4 weeks ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 4:05 PM EST - 6 weeks ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Oct 22, 2025, 7:30 AM EDT - 7 weeks ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Sep 3, 2025, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Aug 13, 2025, 7:00 AM EDT - 4 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 29, 2025, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

ProMIS Neurosciences Announces Private Placement Financing

Jul 28, 2025, 7:00 AM EDT - 5 months ago

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jul 21, 2025, 8:00 AM EDT - 5 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 7 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 31, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 24, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 13, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Mar 11, 2025, 7:30 AM EDT - 9 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 10 months ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 11 months ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 4:15 PM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Mar 11, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences, Inc. Announces Leadership Transition

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

ProMIS Announces Completion of Continuance

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

Jun 30, 2023, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

Jun 29, 2023, 8:00 AM EDT - 2 years ago

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

7DAYSDIMENSIONS
7DAYSDIMENSIONS Dec. 15 at 5:08 PM
$PMN who has the feeling that this dog will jump up in the sky before Xmas? Gut feeling anyone?
1 · Reply
tommy_john
tommy_john Dec. 11 at 12:33 AM
$PMN more upside
0 · Reply
Misterx69
Misterx69 Dec. 10 at 9:04 PM
$PMN
0 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS Dec. 10 at 8:15 PM
$PMN I don't recall seeing a stock going up after a reverse split. Here is one... My first shares were bought at 312.50$... it's a total disaster.
2 · Reply
DaBullRunner
DaBullRunner Dec. 8 at 11:38 PM
$PMN watching closely …. 🚨KITT🚨smart money adding here as this is heavily lagging behind its peers RR and SERV…. Sooner or later this will pay me HUGE I’m even willing to put some of my COIN TSLA profits into KITT👇💰💰💰
0 · Reply
TheUnmaker
TheUnmaker Dec. 8 at 2:52 AM
$TNXP and $PMN my top biotechnology stocks for this week. Huge potential!
1 · Reply
TheUnmaker
TheUnmaker Dec. 6 at 5:28 PM
$TNXP added to my position yesterday after seeing the support at $19.50. This company has always had huge potential. I'm also watch $PMN after the recent split. Low floater 2.15M shares with an end of day pop.
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 3:59 PM
HC Wainwright & Co. has updated their rating for ProMIS Neurosciences ( $PMN ) to Buy with a price target of 18.
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 1 at 2:58 PM
$PMN has popped 8% higher to 7% (~30Kv) moments ago, follow for more volatility.
0 · Reply
TwongStocks
TwongStocks Nov. 28 at 6:57 PM
Today's reverse split results. $IVF 1 for 8 Previous close $0.2529, $2.0232 split-adjusted Intraday high $2.25 Today's close $2.2450 🟢Up 10.96% $PLRZ 1 for 6 Previous close $0.522, $3.132 split-adjusted Intraday high $3.64 Today's close $3.21 🟢Up 2.49% $PMN 1 for 25 Previous close $0.2895, $7.2375 split-adjusted Intraday high $7.92 Today's close $6.76 🔴Down 6.60%
0 · Reply
MTRADe_01
MTRADe_01 Nov. 28 at 5:07 PM
Did a full scan today for high-upside plays w/ volume + narrative + days-to-cover. My top specs: $BEAT, $ONMD, $PMN. Passing on $SMX up here – feels like pure mania. Trade your plan, not your FOMO. 💀📊
0 · Reply
TraderMain
TraderMain Nov. 28 at 4:10 PM
$PMN Strate Garbage Company, I warn my fellow Twitties to get out, b4 you lose it all😠
1 · Reply
SPYmyQQQ
SPYmyQQQ Nov. 28 at 3:26 PM
🎯 Target Hit 🏁 📨 From Nov 3, 2025 💊 $PMN 💵 Entry: $0.4050 ✅ Ext: $0.4748 💰 P/L: +17.23% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
asymmetricvalue
asymmetricvalue Nov. 28 at 2:41 PM
$PMN Yep. This is what we get for not blocking the reverse split. OTC is far less detrimental to shareholders than the ability for this to exponentially lower.
0 · Reply
TwongStocks
TwongStocks Nov. 28 at 12:12 PM
$IVF $PLRZ $PMN All three with reverse splits today. Trading is scheduled to resume at 9:00am ET with the RS in effect. RS details in the quoted post.
0 · Reply
tommy_john
tommy_john Nov. 27 at 4:41 AM
$PMN Split and run
0 · Reply
YungnredE
YungnredE Nov. 27 at 2:08 AM
$PMN Yeah will definitely get there... after the R/s
1 · Reply
YungnredE
YungnredE Nov. 27 at 2:07 AM
$PMN Nobody even knows this stock exists. I thought it would be delisted by now.
0 · Reply
TwongStocks
TwongStocks Nov. 26 at 11:41 PM
I am aware of three NASDAQ reverse splits on Friday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Friday morning. $IVF 1 for 8. Will reduce outstanding shares from approx 15.13m to approx 1.89m. Previously did a 1 for 3 RS on July 21 that reduce OS to approx 928k. OS increased by approx 14.2m since the July RS. $PLRZ 1 for 6. Will reduce outstanding shares from approx 6.25m to approx 1.04m. Previously did a 1 for 250 RS on May 27 which reduced the OS to approx 5.33m. OS increased by approx 1m since the May RS. $PMN 1 for 25. Will reduce outstanding shares from approx 53.81m to approx 2.15m.
0 · Reply
TraderMain
TraderMain Nov. 25 at 11:16 PM
$PMN These companies are💩💩💩💩!!
0 · Reply
TwongStocks
TwongStocks Nov. 25 at 9:08 PM
$PMN NASDAQ Equity Corporate Actions Alert # 2025 - 635 Information Regarding the Reverse Stock Split and CUSIP Number Change for ProMIS Neurosciences Inc. (PMN) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-635 ProMIS Neurosciences Inc. (PMN) will effect a one-for-twenty five (1-25) reverse split of its Common Shares. The reverse stock split will become effective on Friday, November 28, 2025. In conjunction with the reverse split, the CUSIP number will change to 74346M505.
0 · Reply